Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis

2014 ◽  
Vol 29 (6) ◽  
pp. 1148-1155 ◽  
Author(s):  
H. Saeki ◽  
H. Nakagawa ◽  
T. Ishii ◽  
Y. Morisaki ◽  
T. Aoki ◽  
...  
Keyword(s):  
Plaque Psoriasis ◽  
Japanese Patients ◽  
Pustular Psoriasis ◽  
Efficacy And Safety ◽  
Open Label ◽  
Severe Plaque Psoriasis ◽  
Generalized Pustular Psoriasis ◽  
Erythrodermic Psoriasis

scholarly journals Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the Susta IMM phase 2/3 trial

2019 ◽  
Vol 46 (8) ◽  
pp. 686-694 ◽  
Author(s):  
Mamitaro Ohtsuki ◽  
Hideki Fujita ◽  
Mitsunori Watanabe ◽  
Keiko Suzaki ◽  
Mary Flack ◽  
...  
Keyword(s):  
Plaque Psoriasis ◽  
Japanese Patients ◽  
Phase 2 ◽  
Efficacy And Safety ◽  
Severe Plaque Psoriasis

Pilot Study to Evaluate the Efficacy and Safety of Oral Tacrolimus in Adult Patients With Refractory Severe Plaque Psoriasis

2015 ◽  
Vol 20 (3) ◽  
pp. 228-232 ◽  
Author(s):  
Ankit Mittal ◽  
Sunil Dogra ◽  
Tarun Narang ◽  
Aman Sharma
Keyword(s):  
Pilot Study ◽  
Plaque Psoriasis ◽  
Severity Index ◽  
Term Treatment ◽  
Adult Patients ◽  
Efficacy And Safety ◽  
Open Label ◽  
Short Term Treatment ◽  
Psoriasis Area Severity Index ◽  
Severe Plaque Psoriasis

Background: Tacrolimus, a congener of cyclosporine, has replaced cyclosporine as a first-line treatment for most transplant patients due to its superior efficacy and safety. Tacrolimus has not been extensively studied for the treatment of psoriasis. Objectives: To study the efficacy and safety of oral tacrolimus in adult patients with severe refractory plaque psoriasis. Methods: This was an open-label pilot study. Patients with severe plaque type psoriasis who were unresponsive to at least 1 systemic treatment were treated with oral tacrolimus. Results: Thirty patients were treated. After 12 weeks, improvement in mean Psoriasis Area Severity Index (PASI) score was 80.37% ( P < .001), PASI 75 was observed in 19 of 26 (73.1%) patients, and PASI 90 was observed in 11 of 26 (42.3%) patients. No severe side effects were noted. Conclusion: Oral tacrolimus is an effective and safe option for the short-term treatment of severe plaque psoriasis.

scholarly journals Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1)

2017 ◽  
Vol 44 (11) ◽  
pp. 1285-1290 ◽  
Author(s):  
Shinichi Imafuku ◽  
Hitoe Torisu-Itakura ◽  
Atsushi Nishikawa ◽  
Fangyi Zhao ◽  
Gregory S. Cameron ◽  
...  
Keyword(s):  
Plaque Psoriasis ◽  
Subgroup Analysis ◽  
Japanese Patients ◽  
Efficacy And Safety ◽  
Phase 3 ◽  
Severe Plaque Psoriasis
Sign in / Sign up

Export Citation Format

Share Document